TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Brief Summary: Demonstrate superiority of secukinumab over ustekinumab in treatment of moderate to severe plaque psoriasis.


Options:
A: Arm Label: Secukinumab 300 mg; Type: EXPERIMENTAL; Interventions: Biological: Secukinumab | Arm Label: Narrow-band ultraviolet B (nb-UVB); Type: ACTIVE_COMPARATOR; Interventions: Radiation: nb-UVB | Intervention Type: BIOLOGICAL; Name: Secukinumab; Assigned to Arm(s): Secukinumab 300 mg | Intervention Type: RADIATION; Name: nb-UVB; Assigned to Arm(s): Narrow-band ultraviolet B (nb-UVB)
B: Arm Label: 80 mg Ixekizumab Auto-Injector; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab Auto-Injector | Arm Label: 80 mg Ixekizumab Prefilled Syringe; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab Prefilled Syringe | Intervention Type: DRUG; Name: Ixekizumab Auto-Injector; Assigned to Arm(s): 80 mg Ixekizumab Auto-Injector | Intervention Type: DRUG; Name: Ixekizumab Prefilled Syringe; Assigned to Arm(s): 80 mg Ixekizumab Prefilled Syringe
C: Arm Label: Secukinumab; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab | Arm Label: Ustekinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ustekinumab | Intervention Type: DRUG; Name: Secukinumab; Assigned to Arm(s): Secukinumab | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Ustekinumab
D: Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Brief Summary: Demonstrate superiority of secukinumab over ustekinumab in treatment of moderate to severe plaque psoriasis.


Options:
A: Arm Label: adalimumab + placebo; Type: ACTIVE_COMPARATOR; Interventions: Biological: adalimumab, Drug: placebo (vehicle ointment) | Arm Label: adalimumab + calcipotriol/betamethasone; Type: ACTIVE_COMPARATOR; Interventions: Biological: adalimumab, Drug: Calcipotriol/Betamethasone Ointment | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): adalimumab + calcipotriol/betamethasone, adalimumab + placebo | Intervention Type: DRUG; Name: Calcipotriol/Betamethasone Ointment; Assigned to Arm(s): adalimumab + calcipotriol/betamethasone | Intervention Type: DRUG; Name: placebo (vehicle ointment); Assigned to Arm(s): adalimumab + placebo
B: Arm Label: Treatment Group A; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 Ointment 1 | Arm Label: Treatment Group B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle 1 | Arm Label: Treatment Group C; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 Ointment 2 | Arm Label: Treatment Group D; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle 2 | Intervention Type: DRUG; Name: CP-690,550 Ointment 1; Assigned to Arm(s): Treatment Group A | Intervention Type: DRUG; Name: Vehicle 1; Assigned to Arm(s): Treatment Group B | Intervention Type: DRUG; Name: CP-690,550 Ointment 2; Assigned to Arm(s): Treatment Group C | Intervention Type: DRUG; Name: Vehicle 2; Assigned to Arm(s): Treatment Group D
C: Arm Label: Secukinumab; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab | Arm Label: Ustekinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ustekinumab | Intervention Type: DRUG; Name: Secukinumab; Assigned to Arm(s): Secukinumab | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Ustekinumab
D: Arm Label: Placebo/Adalimumab; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Biological: Adalimumab | Arm Label: Adalimumab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Adalimumab | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo/Adalimumab | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Adalimumab, Placebo/Adalimumab

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Use of Proteus Discover to Enable Improved Clinical Outcomes in Subjects With Uncontrolled Hypertension and Type 2 Diabetes Mellitus: A Pilot Study
Brief Summary: The purpose of this study was to evaluate the efficacy of a new digital health offering, Proteus Discover to lower blood pressure and glycated hemoglobin in patients with uncontrolled hypertension and type 2 diabetes.


Options:
A: Arm Label: DH-4; Type: ACTIVE_COMPARATOR; Interventions: Other: Proteus Discover | Arm Label: DH-12; Type: ACTIVE_COMPARATOR; Interventions: Other: Proteus Discover | Arm Label: Usual Care; Type: OTHER; Interventions: Other: Usual Care | Intervention Type: OTHER; Name: Proteus Discover; Assigned to Arm(s): DH-12, DH-4 | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care
B: Arm Label: T2DM patients seen in routine practice; Type: N/A; Interventions: Other: No treatment given | Intervention Type: OTHER; Name: No treatment given; Assigned to Arm(s): T2DM patients seen in routine practice
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Home Telehealth with Behavioral Education Component | Intervention Type: BEHAVIORAL; Name: Home Telehealth with Behavioral Education Component; Assigned to Arm(s): Intervention
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Toolkit | Arm Label: Control; Type: OTHER; Interventions: Other: Control | Intervention Type: OTHER; Name: Toolkit; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Smart Phone Medication Adherence Saves Kidneys--SMASK
Brief Summary: Investigators will employ a 2-arm Randomized Controlled Trial (RCT) design with the subject as the unit of randomization and analysis. Kidney transplant recipients having uncontrolled hypertension will be enrolled into a screening phase to measure medication non-adherence. Each subject will use an electronic pill tray for 1 month without any reminder functions activated. Non-adherent subjects who remain uncontrolled will be randomly assigned to SMASK or Standard Care (SC). SC will continue to use the pill tray with reminders turned off and will receive attention control texts with healthy lifestyle information. SMASK will have the reminder functions of the electronic pill tray activated and will receive a Bluetooth blood pressure monitor and an app to collect the data and send to researchers.

Subjects in the second phase will participate in 4 more evaluations at months 1, 3, 6, 12 post randomization. Research staff will measure resting blood pressure and heart rate.


Options:
A: Arm Label: Telemetric Intervention Arm; Type: EXPERIMENTAL; Interventions: Behavioral: Telemetric Intervention | Arm Label: Standard of Care Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Telemetric Intervention; Assigned to Arm(s): Telemetric Intervention Arm
B: Arm Label: SMASK; Type: EXPERIMENTAL; Interventions: Behavioral: SMASK | Arm Label: EnhancedSC; Type: OTHER; Interventions: Behavioral: EnhancedSC | Intervention Type: BEHAVIORAL; Name: SMASK; Assigned to Arm(s): SMASK | Intervention Type: BEHAVIORAL; Name: EnhancedSC; Assigned to Arm(s): EnhancedSC
C: Arm Label: Arm A-Tacrolimus then Envarsus; Type: EXPERIMENTAL; Interventions: Drug: Envarsus XR, Drug: Tacrolimus | Arm Label: Arm B-Envarsus then Tacrolimus; Type: EXPERIMENTAL; Interventions: Drug: Envarsus XR, Drug: Tacrolimus | Intervention Type: DRUG; Name: Envarsus XR; Assigned to Arm(s): Arm A-Tacrolimus then Envarsus, Arm B-Envarsus then Tacrolimus | Intervention Type: DRUG; Name: Tacrolimus; Assigned to Arm(s): Arm A-Tacrolimus then Envarsus, Arm B-Envarsus then Tacrolimus
D: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Contract | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Behavioral Contract; Assigned to Arm(s): Intervention Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of a Monitoring Device for Patients With Cancer Treated Using Oral Therapeutics
Brief Summary: The emergence of oral delivery in cancer therapeutics is expected to result in an increased need for better coordination between all treatment stakeholders, mainly to ensure adequate treatment delivery to the patient. There is significant interest in the nurse navigation program's potential to improve transitions of care by improving communication between treatment stakeholders and by providing personalized organizational assistance to patients. The use of health information technology is another strategy aimed at improving cancer care coordination that can be combined with the NN program to improve remote patient follow-up. However, the potential of these two strategies combined to improve oral treatment delivery is limited by a lack of rigorous evidence of actual impact.

The investigators are conducting a large scale randomized controlled trial designed to assess the impact of a navigation program denoted CAPRI that is based on two Nurse Navigators and a web portal ensuring coordination between community and hospital as well as between patients and navigators, versus routine delivery of oral anticancer therapy. The primary research aim is to assess the impact of the program on treatment delivery for patients with metastatic cancer, as measured by Relative Dose Intensity. The trial involves a number of other outcomes, including toxic side effects, patient quality of life and patient experience . An economic evaluation adopting a societal perspective will be conducted, in order to estimate those health care resources' used. A parallel process evaluation will be conducted to describe implementation of the intervention


Options:
A: Arm Label: SINEMA intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: SINEMA intervention | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: SINEMA intervention; Assigned to Arm(s): SINEMA intervention group
B: Arm Label: Experimental; Type: N/A; Interventions: Other: CAPRI | Arm Label: Control; Type: N/A; Interventions: N/A | Intervention Type: OTHER; Name: CAPRI; Assigned to Arm(s): Experimental
C: Arm Label: Standard consultation; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard care in orthopaedic outpatient clinic | Arm Label: Telemedicine consultation; Type: EXPERIMENTAL; Interventions: Other: Telemedicine consultation | Intervention Type: OTHER; Name: Telemedicine consultation; Assigned to Arm(s): Telemedicine consultation | Intervention Type: OTHER; Name: Standard care in orthopaedic outpatient clinic; Assigned to Arm(s): Standard consultation
D: Arm Label: Teledermatology; Type: EXPERIMENTAL; Interventions: Other: Teledermatology | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Teledermatology; Assigned to Arm(s): Teledermatology

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trial on Radical Upfront Surgery in Advanced Ovarian Cancer
Brief Summary: This study consists of three parts, whereas Part 1 and Part 2 are performed in Germany only, and Part 3 is a multinational trial.

All patients with suspicion of advanced ovarian cancer are detected in the participating study centers in a pre-screening. The study centers will register all patients with suspected ovarian cancer in a screening log. After the patients have given informed consent, they can be enrolled in different parts of the study.

TRUST-Trial: This part compares two strategies in the therapy of advanced ovarian cancer. En detail, this part of the trial will evaluate if one of two strategies of timing surgery within the therapeutic procedures may show any significant advances in terms of overall survival over the other.


Options:
A: Arm Label: Arm I PDS and chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: PDS (Primary Debulkdung Surgery), Procedure: 6 cycles of standard chemotherapy | Arm Label: Arm II Timing of surgery after 3 cycles of SOC CTX; Type: EXPERIMENTAL; Interventions: Procedure: Timing of surgery after 3 cycles of standard NACT, IDS, Procedure: IDS, Drug: 3 cycles of standard chemotherapy | Intervention Type: PROCEDURE; Name: PDS (Primary Debulkdung Surgery); Assigned to Arm(s): Arm I PDS and chemotherapy | Intervention Type: PROCEDURE; Name: 6 cycles of standard chemotherapy; Assigned to Arm(s): Arm I PDS and chemotherapy | Intervention Type: PROCEDURE; Name: Timing of surgery after 3 cycles of standard NACT, IDS; Assigned to Arm(s): Arm II Timing of surgery after 3 cycles of SOC CTX | Intervention Type: PROCEDURE; Name: IDS; Assigned to Arm(s): Arm II Timing of surgery after 3 cycles of SOC CTX | Intervention Type: DRUG; Name: 3 cycles of standard chemotherapy; Assigned to Arm(s): Arm II Timing of surgery after 3 cycles of SOC CTX
B: Intervention Type: DRUG; Name: Neoadjuvant chemotherapy (Paclitaxel and Carboplatin); Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: neoadjuvant therapy; Assigned to Arm(s): N/A
D: Arm Label: Primary debulking surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Primary Debulking Surgery + Adjuvant Chemotherapy | Arm Label: Interval debulking surgery; Type: EXPERIMENTAL; Interventions: Drug: Neoadjuvant chemotherapy + Interval Debulking Surgery | Intervention Type: DRUG; Name: Neoadjuvant chemotherapy + Interval Debulking Surgery; Assigned to Arm(s): Interval debulking surgery | Intervention Type: PROCEDURE; Name: Primary Debulking Surgery + Adjuvant Chemotherapy; Assigned to Arm(s): Primary debulking surgery

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Peri-articular Tranexamic Acid Injection in Total Knee Arthroplasty: A Randomized Controlled Trial
Brief Summary: This study evaluates the peri-articular tranexamic acid injection in total knee arthroplasty which is an alternative route of administration for blood loss reduction. Half of participants will receive intravenous tranexamic acid injection, while the other half will receive peri-articular tranexamic acid injection during total knee arthroplasty.


Options:
A: Intervention Type: DRUG; Name: IV Tranexamic acid 10mg/kg pt body weight; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Quixil topical sealant; Assigned to Arm(s): N/A
B: Arm Label: Vitagel; Type: EXPERIMENTAL; Interventions: Device: Vitagel | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Vitagel; Assigned to Arm(s): Vitagel
C: Arm Label: Peri-articular group; Type: EXPERIMENTAL; Interventions: Drug: Peri-articular tranexamic acid | Arm Label: Intravenous group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous tranexamic acid | Intervention Type: DRUG; Name: Peri-articular tranexamic acid; Assigned to Arm(s): Peri-articular group | Intervention Type: DRUG; Name: Intravenous tranexamic acid; Assigned to Arm(s): Intravenous group
D: Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline (0.9% NaCl) | Arm Label: Topical; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic Acid, Drug: Normal saline (0.9% NaCl) | Arm Label: Systemic; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic Acid, Drug: Normal saline (0.9% NaCl) | Intervention Type: DRUG; Name: Tranexamic Acid; Assigned to Arm(s): Systemic, Topical | Intervention Type: DRUG; Name: Normal saline (0.9% NaCl); Assigned to Arm(s): Control, Systemic, Topical

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: 12 Weeks Weight Loss Study Using Feedback Messages Delivered Via Smartphone
Brief Summary: Brief Summary: This randomized clinical pilot will test the feasibility of having individuals self-monitor for 12 weeks and based on what the participants record be given feedback messages. The investigator will use this information to refine the questions and data collection procedures for the larger study.

Participants will be randomized into 3 groups

* self-monitoring only
* self-monitoring w/ feedback messages
* self-monitoring w/feedback messages and group sessions Feedback messages will be delivered up to 4 times per day using a different schedule. The group sessions will be held in the 2nd, 4th and 8th week of the 12-week study.

All participants will be asked to complete questionnaires and 2 assessment visits at baseline and 12 weeks.


Options:
A: Arm Label: intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: APP + health advice | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: health advice | Intervention Type: BEHAVIORAL; Name: APP + health advice; Assigned to Arm(s): intervention group | Intervention Type: BEHAVIORAL; Name: health advice; Assigned to Arm(s): control group
B: Arm Label: Experimental: Group Sessions; Type: EXPERIMENTAL; Interventions: Behavioral: Group Sessions, Behavioral: Feedback, Behavioral: Self-monitoring | Arm Label: Active Comparator: Self-Monitoring; Type: EXPERIMENTAL; Interventions: Behavioral: Self-monitoring | Arm Label: Experimental: Feedback; Type: EXPERIMENTAL; Interventions: Behavioral: Feedback, Behavioral: Self-monitoring | Intervention Type: BEHAVIORAL; Name: Group Sessions; Assigned to Arm(s): Experimental: Group Sessions | Intervention Type: BEHAVIORAL; Name: Feedback; Assigned to Arm(s): Experimental: Feedback, Experimental: Group Sessions | Intervention Type: BEHAVIORAL; Name: Self-monitoring; Assigned to Arm(s): Active Comparator: Self-Monitoring, Experimental: Feedback, Experimental: Group Sessions
C: Arm Label: Physical Activity; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Activity | Arm Label: Wellness Contact Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Wellness | Intervention Type: BEHAVIORAL; Name: Physical Activity; Assigned to Arm(s): Physical Activity | Intervention Type: BEHAVIORAL; Name: Wellness; Assigned to Arm(s): Wellness Contact Control
D: Arm Label: Photo App; Type: EXPERIMENTAL; Interventions: Behavioral: Photo App, Behavioral: Podcasts | Arm Label: Diet App; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diet App, Behavioral: Podcasts | Intervention Type: BEHAVIORAL; Name: Photo App; Assigned to Arm(s): Photo App | Intervention Type: BEHAVIORAL; Name: Diet App; Assigned to Arm(s): Diet App | Intervention Type: BEHAVIORAL; Name: Podcasts; Assigned to Arm(s): Diet App, Photo App

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clarithromycin as Adjuvant to Periodontal Debridement in the Treatment of Generalized Aggressive Periodontitis: Randomized Clinical Trial
Brief Summary: To assess the periodontal clinical response and the possible adverse effects of the clarithromycin combined to periodontal mechanical therapy in the treatment of patients with generalized aggressive periodontitis.


Options:
A: Arm Label: Biannual mass oral azithromycin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Biannual mass oral placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Biannual mass oral azithromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Biannual mass oral placebo
B: Arm Label: clarithromycin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clarithromycin, Other: One-stage full-mouth ultrasonic debridement (FMUD) | Arm Label: placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Other: One-stage full-mouth ultrasonic debridement (FMUD) | Intervention Type: DRUG; Name: Clarithromycin; Assigned to Arm(s): clarithromycin group | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo group | Intervention Type: OTHER; Name: One-stage full-mouth ultrasonic debridement (FMUD); Assigned to Arm(s): clarithromycin group, placebo group
C: Arm Label: Azithromycin treatment 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Placebo 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin treatment 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo 2
D: Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: azithromycin 250 mg tablets | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo tablets | Intervention Type: DRUG; Name: azithromycin 250 mg tablets; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: placebo tablets; Assigned to Arm(s): Placebo

Answer: B